Juventas Therapeutics completes enrollment of Phase I/II RETRO-HF trial

Press release provided by Bioenterprise Corporation – Juventas Therapeutics.

Juventas Therapeutics Inc. a private clinical-stage company developing a drug-based approach to regenerative medicine today announced that it successfully completed the Phase I arm of the RETRO-HF clinical trial and fully enrolled the Phase II arm that is evaluating the safety and preliminary clinical efficacy for retrograde infusion of JVS-100 in patients with heart failure.

Click here to read the complete release.

Originally published August 12, 2014.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: